Mast cell involvement in fibrodysplasia ossificans progressiva

被引:85
作者
Gannon, FH
Glaser, D
Caron, R
Thompson, LDR
Shore, EM
Kaplan, FS
机构
[1] Univ Penn, Med Ctr,Sch Med, Dept Orthopaed, Div Mol Orthopaed, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA
[4] Armed Forces Inst Pathol, Dept Orthopaed Pathol, Washington, DC 20306 USA
[5] Armed Forces Inst Pathol, Dept Otorhinolaryngol Pathol, Washington, DC 20306 USA
关键词
mast cells; fibrodysplasia ossificans progressiva; heterotopic ossification; osteogenesis;
D O I
10.1053/hupa.2001.26464
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Fibrodysplasia ossificans progressiva (FOP) is a catastrophic genetic disorder of progressive heterotopic ossification associated with dysregulated production of bone morphogenetic protein 4 (BMP4), a potent osteogenic morphogen. Postnatal heterotopic ossification in FOP is often heralded by hectic episodes of severe posttraumatic connective tissue swelling and intramuscular edema, followed by an intense and highly angiogenic fibroproliferative mass. The abrupt appearance, intense size, and rapid intrafascial spread of the edematous preosseous fibroproliferative lesions implicate a dysregulated wound response mechanism and suggest that cells and mediators involved in inflammation and tissue repair may be conscripted in the growth and progression of FOP lesions. The central and coordinate role of inflammatory mast cells and their mediators in tissue edema, wound repair, fibrogenesis, angiogenesis, and tumor invasion prompted us to investigate the potential involvement of mast cells in the pathology of FOP lesions. We show that inflammatory mast cells are present at every stage of the development of FOP lesions and are most pronounced at the highly vascular fibroproliferative stage. Mast cell density at the periphery of FOP lesional tissue is 40- to 150-fold greater than in normal control skeletal muscle or in uninvolved skeletal muscle from FOP patients and 10- to 40-fold greater than in any other inflammatory myopathy examined. These findings document mobilization and activation of inflammatory mast cells in the pathology of FOP lesions and provide a novel and previously unrecognized target for pharmacologic intervention in this extremely disabling disease. Hurt PATHOL 32;842-848. Thus is a US government work. There are no restrictions on its use.
引用
收藏
页码:842 / 848
页数:7
相关论文
共 52 条
[1]   DETECTION OF THE MAJOR URINARY METABOLITE OF PROSTAGLANDIN D-2 IN THE CIRCULATION - DEMONSTRATION OF ELEVATED LEVELS IN PATIENTS WITH DISORDERS OF SYSTEMIC MAST-CELL ACTIVATION [J].
AWAD, JA ;
MORROW, JD ;
ROBERTS, LJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 93 (05) :817-824
[2]   Therapeutic strategies for allergic diseases [J].
Barnes, PJ .
NATURE, 1999, 402 (6760) :B31-B38
[3]   Activated T lymphocytes induce degranulation and cytokine production by human mast cells following cell-to-cell contact [J].
Bhattacharyya, SP ;
Drucker, I ;
Reshef, T ;
Kirshenbaum, AS ;
Metcalfe, DD ;
Mekori, YA .
JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 63 (03) :337-341
[4]   Human mast cells stimulate vascular tribe formation - Tryptase is a novel, potent angiogenic factor [J].
Blair, RJ ;
Meng, H ;
Marchese, MJ ;
Ren, SL ;
Schwartz, LB ;
Tonnesen, MG ;
Gruber, BL .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (11) :2691-2700
[5]   THE NATURAL-HISTORY OF HETEROTOPIC OSSIFICATION IN PATIENTS WHO HAVE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - A STUDY OF 44 PATIENTS [J].
COHEN, RB ;
HAHN, GV ;
TABAS, JA ;
PEEPER, J ;
LEVITZ, CL ;
SANDO, A ;
SANDO, N ;
ZASLOFF, M ;
KAPLAN, FS .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1993, 75A (02) :215-219
[6]   FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - THE CLINICAL-FEATURES AND NATURAL-HISTORY OF 34 PATIENTS [J].
CONNOR, JM ;
EVANS, DAP .
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1982, 64 (01) :76-83
[7]   Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis [J].
Coussens, LM ;
Raymond, WW ;
Bergers, G ;
Laig-Webster, M ;
Behrendtsen, O ;
Werb, Z ;
Caughey, GH ;
Hanahan, D .
GENES & DEVELOPMENT, 1999, 13 (11) :1382-1397
[8]  
DASTYCH J, 1994, J IMMUNOL, V152, P213
[9]   Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells - In vitro and in vivo evidence in murine systems [J].
Finotto, S ;
Mekori, YA ;
Metcalfe, DD .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) :1721-1728
[10]  
FRIERI M, 1983, J IMMUNOL, V131, P1942